Follow
Aaron D. Levine
Aaron D. Levine
Professor, School of Public Policy, Georgia Tech
Verified email at pubpolicy.gatech.edu
Title
Cited by
Cited by
Year
The transcriptome of Arabidopsis thaliana during systemic acquired resistance
K Maleck, A Levine, T Eulgem, A Morgan, J Schmid, KA Lawton, JL Dangl, ...
Nature genetics 26 (4), 403-410, 2000
12672000
A computational scan for U12-dependent introns in the human genome sequence
A Levine, R Durbin
Nucleic acids research 29 (19), 4006-4013, 2001
1822001
Tracking the rise of stem cell tourism
KA Ryan, AN Sanders, DD Wang, AD Levine
Regenerative medicine 5 (1), 27-33, 2010
1532010
Challenges in the translation and commercialization of cell therapies
BP Dodson, AD Levine
BMC biotechnology 15 (1), 1, 2015
1402015
Self‐Regulation, Compensation, and the Ethical Recruitment of Oocyte Donors
AD Levine
Hastings Center Report 40 (2), 25-36, 2010
1052010
The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies
AD Levine, LE Wolf
Journal of Law, Medicine & Ethics 40 (1), 122-134, 2012
842012
Revisiting the Warnock rule
JB Hurlbut, I Hyun, AD Levine, R Lovell-Badge, JE Lunshof, ...
Nature biotechnology 35 (11), 1029-1042, 2017
682017
Positioning a scientific community on unproven cellular therapies: the 2015 International Society for Cellular Therapy perspective
M Dominici, K Nichols, A Srivastava, DJ Weiss, P Eldridge, N Cuende, ...
Cytotherapy 17 (12), 1663-1666, 2015
492015
Assessing the use of assisted reproductive technology in the United States by non–United States residents
AD Levine, SL Boulet, RM Berry, DJ Jamieson, HB Alberta-Sherer, ...
Fertility and Sterility 108 (5), 815-821, 2017
412017
Identifying under-and overperforming countries in research related to human embryonic stem cells
AD Levine
Cell Stem Cell 2 (6), 521-524, 2008
392008
A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies
K Wang, Y Liu, J Li, B Wang, R Bishop, C White, A Das, AD Levine, L Ho, ...
Cytotherapy 21 (10), 1081-1093, 2019
382019
Policy uncertainty and the conduct of stem cell research
AD Levine
Cell Stem Cell 8 (2), 132-135, 2011
382011
Research policy and the mobility of US stem cell scientists
AD Levine
Nature biotechnology 24 (7), 865-866, 2006
372006
Insights from patients' blogs and the need for systematic data on stem cell tourism
AD Levine
The American Journal of Bioethics 10 (5), 28-29, 2010
292010
Risk disclosure and the recruitment of oocyte donors: are advertisers telling the full story?
HB Alberta, RM Berry, AD Levine
Journal of Law, Medicine & Ethics 42 (2), 232-243, 2014
282014
The oversight and practice of oocyte donation in the United States, United Kingdom and Canada
AD Levine
HEC forum 23, 15-30, 2011
282011
Tracking and assessing the rise of state-funded stem cell research
RN Karmali, NM Jones, AD Levine
Nature Biotechnology 28 (12), 1246-1248, 2010
252010
Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions
DJ Weiss, L Turner, AD Levine, L Ikonomou
Cytotherapy 20 (2), 165-168, 2018
242018
Ethical principles for the use of human cellular biotechnologies
PR Wolpe, KS Rommelfanger, ...
Nature Biotechnology 35 (11), 1050-1058, 2017
242017
The origins of human embryonic stem cell research policies in the US states
AD Levine, TA Lacy, JC Hearn
Science and Public Policy 40 (4), 544-558, 2013
242013
The system can't perform the operation now. Try again later.
Articles 1–20